Tag: Disease
Breaking News
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
TOKYO, Apr 10, 2024 - (JCN Newswire) - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment...
Chiron AS in Trondheim, Norway, Has Developed The World’s First Commercial Microplastic Reference Materials
TRONDHEIM, NORWAY, Apr 9, 2024 - (ACN Newswire) - Chiron AS, now part of ZeptoMetrix®, has developed the world's very first commercially available microplastic reference...
Your Brain Breaks Its Own DNA to Form Memories That Can Last a Lifetime
Some memories last a lifetime. The awe of seeing a full solar eclipse. The first smile you shared with your partner. The glimpse of...
Managing User Focus with :focus-visible
This is going to be the 2nd post in a small series we are doing on form accessibility. If you missed the first post,...
IQT’s “Journal Club:” Quantum Readiness in Healthcare and Public Health: Building a Quantum Literate Workforce – Inside Quantum Technology
By Kenna Hughes-Castleberry posted 05 Apr 2024
IQT’s “Journal Club” is a weekly article series that breaks down...
Quantum News Briefs: April 5, 2024: Classiq and Quantum Intelligence Corp (QIC, Korea) Partner On Quantum Accelerated Drug Development; Keyfactor’s New Command SaaS Lite...
By Kenna Hughes-Castleberry posted 05 Apr 2024
Quantum News Briefs: April 5, 2024: Press release summaries below:
Classiq and...
World Hepatitis Summit 2024 Convenes in Lisbon
LONDON, Apr 4, 2024 - (ACN Newswire) - The World Hepatitis Summit (WHS) 2024 convenes in Lisbon from 9 - 11 April and will bring...
Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization
Vancouver, BC, Apr 3, 2024 - (ACN Newswire) - Clairvoyant Therapeutics Inc. (www.clairvoyantrx.com), the private clinical-stage pharmaceutical company developing psilocybin treatment for alcohol use disorder...
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French...
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French...
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
HONG KONG, China and WILMINGTON, Del., Apr 1, 2024 - (ACN Newswire) - China Medical System Holdings Limited (“CMS” or the “Group”) and Incyte (Nasdaq:INCY)...
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S....
TOKYO and CAMBRIDGE, Mass., Apr 1, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Eisai submitted to the...
Latest Intelligence
